



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory A. Demopoulos et al. Attorney Docket No.: CH.1.0018.US2
Application No.: 10/031,546 Group Art Unit: 1615
Filed: January 18, 2002 Examiner: Micah Paul Young
Title: SOLUTIONS AND METHODS FOR INHIBITION OF PAIN,
INFLAMMATION AND CARTILAGE DEGRADATION

5th SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

January 3, 2006

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. x Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
2. x Pursuant to 37 C.F.R. § 1.97(c), this 5th Supplemental Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, and is accompanied by:
 - a. x the submission fee set forth in 37 C.F.R. § 1.17(p). Check No. 7837 in the amount of \$180.00 is enclosed.
3. x The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 502230. This authorization also hereby includes a request for any extensions of time of the

01/10/2006 FFANAI2 00000046 10031546

02 FC:1806

180.00 0P

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

OMEROS CORPORATION



Marcia S. Kelbon
VP, Patent & General Counsel
Registration No. 34,358
Direct Dial No. 206.676.5020


I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

1/3/06
Date

Stj
Stephanie Jansen

MSK:sj

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688



**INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL
TO THE PROSECUTION OF THE SUBJECT APPLICATION**

Applicants: Gregory A. Demopoulos et al. Attorney Docket No: CH.1.0018.US2
Serial No: 10/031,546 Group Art Unit: 1615
Filed: January 18, 2002 Examiner: Micah Paul Young
Title: SOLUTIONS AND METHODS FOR INHIBITION OF PAIN, INFLAMMATION
AND CARTILAGE DEGRADATION

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner

Initial	ID	Document Information
_____	O00549	Taskiran, D., et al. "Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1," <i>Biochem Biophys Res Commun</i> 200(1) :142-8 (1994). Abstract only
_____	O00727	Studer, R., et al., "Nitric oxide in osteoarthritis," <i>Osteoarthritis and Cartilage</i> 7 :377-379 (1999).
_____	O00728	Blanco Garcia, F.J., "Catabolic events in osteoarthritic cartilage," <i>Osteoarthritis and Cartilage</i> 7 :308-309 (1999).
_____	O00844	van den Berg, W.B., et al, "Tissue Engineering, Cells, Scaffolds, and Growth Factors: Growth Factors and Cartilage Repair," <i>Clinical Orthopaedics and Related Research</i> 391S :S244-S250 (2001).
_____	O01280	Neumann, E., et al., "Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway," <i>Gene Therapy</i> 9 :1508-1519 (2002).
_____	O01325	Henrotin, Y. et al., "Anabolic events in osteoarthritis," <i>Osteoarthritis and Cartilage</i> 7 :310-312 (1999).

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

- _____ O01697 Haupt, J.L., et al., "Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model," *Journal of Orthopaedic Research* **23**:118-126 (2005).
- _____ O01733 Studer, R.K., et al., "Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition," *Arthritis Research & Therapy* **6**(1):R56-R64 (2004).
- _____ O01734 Studer, R.K., et al., "p38 MAPK and COX2 inhibition modulate human chondrocyte response to TGF- β ," *Journal of Orthopaedic Research* **23**:454-461 (2005).
- _____ O01735 Studer, R.K., et al., "Nitric oxide inhibition of IGF-1 stimulated proteoglycan synthesis: role of cGMP," *Journal of Orthopaedic Research* **21**:914-921 (2003).
- _____ O01745 Studer, R.K., et al., "Nitric oxide inhibits chondrocyte response to IGF-1: inhibition of IGF-IR β tyrosine phosphorylation," *Am J Physiol Cell Physiol* **279**:C961-C969 (2000).

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MSK:sj

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688